




To the Editor: We have read with great interest the paper by
Praditpornsilpa et al.1 and the related comment by Wish2
about induction of neutralizing antibodies by biosimilar
epoetin products in Thailand. As far as we know, the only
Argentine-manufactured epoetin marketed in Thailand is
Hemax (Bio Sidus SA, Buenos Aires, Argentina), which is
probably the Argentine product mentioned in Pradit-
pornsilpa’s report, together with products of other origins.
The induction of such antibodies seems to be a class effect of
erythropoiesis stimulators and we agree that it is shared by
biosimilar and innovator epoetins. This concept emphasizes
the importance of a pharmacovigilance plan and risk minimi-
zation strategies for epoetin products. However, some statements
in both articles can be misleading, including the putative
existence of a pure red-cell aplasia (PRCA) epidemic induced
by biosimilar epoetins in Thailand and the assumption that
no pharmacovigilance is performed for such products.
A point estimation of antibodies and aplasia (as in the report
by Praditpornsilpa et al.1) does not mean/demonstrate the
existence of epidemic PRCA induced by biosimilars, as sug-
gested by Wish.2 Hemax was registered in Argentina in 1990,
before the biosimilarity concept arose in Europe, and its
formulation has remained unchanged. Pharmacovigilance
activities on Hemax include antibodies detection since 1998.
Hemax has been in the Thai market since 1997 and, upon
requirement of the local licensee, since February 2004 (after
the outbreak of PRCA associated to an innovator epoetin
product and related to formulation changes), we began to
receive sera for anti-epoetin testing from a few patients
treated with Hemax that reported loss of efﬁcacy. We suspect
that the increased rate of requirements for anti-epoetin antibodies
fromThailand reﬂects the increased interest on PRCA triggered
by the epidemics associated to Eprex, in a country in which
the rate of aplastic anemia is higher than in Western countries,3
involving probably human leukocyte antigen background.
The worldwide rate of PRCA associated to Hemax,
estimated in 2007 in 1.21 cases per 100,000 treatment-years,4
seems similar to reports with other epoetins, excluding the
already mentioned epidemics induced by Eprex.
A prospective study, including data from all epoetin
marketed in Thailand, as the one currently under way by the
Thai FDA (together with three Thai scientiﬁc societies),
should provide a more precise assessment of prevalence and
association between PRCA and epoetin products.
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The Author Replies: Ferro and Gonzalez1 describe as mis-
leading statements in the article by Praditpornsilpa et al.2 and
in the accompanying commentary by this author3 that there
was an epidemic of pure red cell aplasia (PRCA) in Thailand,
and that it was caused by the use of biosimilar erythropoiesis-
stimulating agents (ESAs). One could dispute that 23 patients
with PRCA who were receiving biosimilar ESAs in Thailand
constitutes an epidemic based on patient counts, but an
incidence rate of 1:2068 is certainly alarming when compared
with the virtual absence of ESA-associated PRCA in the
United States where biosimilar ESAs are not used. Whether
the incidence of PRCA associated with biosimilar ESA use is
signiﬁcantly higher than the background incidence of PRCA
in Thailand unassociated with ESA use was not addressed
by Praditpornsilpa et al.,2 but this question underscores the
importance of tailoring the post-marketing pharmacovigilance
program to the speciﬁc patient characteristics of each country
as the immunogenicity of biosimilars and other therapeutic
agents has a genetic predisposition. That said, a high back-
ground rate of idiopathic PRCA, an autoimmune disease, in
Thailand should be cause for more pharmacovigilance in that
country, not less. Irrespective of whether the current state of
pharmacovigilance for biosimilar ESAs is currently adequate
to assure the safety of patients receiving these agents, this
author agrees with Ferro and Gonzalez, Praditpornsilpa et al.,2
and drug regulatory agencies throughout the world that it can
be better, especially as increasing numbers of biosimilar agents
become available and their market share vs. the reference
agent increases because of patent expirations and efforts at
cost-containment.
1. Ferro HH, Gonza´lez EB. Biosimilar recombinant human erythropoietin
induces the production of neutralizing antibodies. Kidney Int 2012; 81: 1273.
2. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar
recombinant human erythropoietin induces the production of neutralizing
antibodies. Kidney Int 2011; 80: 88–92.
3. Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: you
can’t fool Mother Nature. Kidney Int 2011; 80: 11–13.
http://www.kidney-international.org l e t te r to the ed i to r
& 2012 International Society of Nephrology
Kidney International (2012) 81, 1273–1279 1273
